NO20003721L - Farmasøytisk aktivt morfolinol - Google Patents

Farmasøytisk aktivt morfolinol

Info

Publication number
NO20003721L
NO20003721L NO20003721A NO20003721A NO20003721L NO 20003721 L NO20003721 L NO 20003721L NO 20003721 A NO20003721 A NO 20003721A NO 20003721 A NO20003721 A NO 20003721A NO 20003721 L NO20003721 L NO 20003721L
Authority
NO
Norway
Prior art keywords
morpholinol
pharmaceutically active
solvates
disease
compound
Prior art date
Application number
NO20003721A
Other languages
English (en)
Other versions
NO20003721D0 (no
NO326878B1 (no
Inventor
Phillip Frederick Morgan
David Lee Musso
John Joseph Partidge
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20003721D0 publication Critical patent/NO20003721D0/no
Publication of NO20003721L publication Critical patent/NO20003721L/no
Publication of NO326878B1 publication Critical patent/NO326878B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er beskrevet forbindelsen (+)-(2S,3S)-2-(3-klorofey)-3,,-tty-2-morfolinol og farmasøytisk akseptable salter og solvater derav, farmasøytiske sammensetninger som inneholder disse, og det er også beskrevet en fremgangsmåte for behandling av depresjon, oppmerksomhetredusert hyperaktivitetsforstyrrelse (ADHD), fedme, migrene, smerte, seksuell feilfunksjon, Parkinson sykdom, Alzheimers sykdom eller avhengighet av kokain eller nikotin-inneholdende (spesielt tobakk) produkter ved anvendelse av en slik forbindelse, salter, solvater eller sammensetninger.
NO20003721A 1998-01-21 2000-07-20 Anvendelse av morfolinol NO326878B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22
PCT/US1999/001134 WO1999037305A1 (en) 1998-01-21 1999-01-20 Pharmaceutically active morpholinol

Publications (3)

Publication Number Publication Date
NO20003721D0 NO20003721D0 (no) 2000-07-20
NO20003721L true NO20003721L (no) 2000-09-19
NO326878B1 NO326878B1 (no) 2009-03-09

Family

ID=26312986

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20003721A NO326878B1 (no) 1998-01-21 2000-07-20 Anvendelse av morfolinol
NO20083529A NO20083529L (no) 1998-01-21 2008-08-14 Farmasoytisk aktivt morfolinol

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20083529A NO20083529L (no) 1998-01-21 2008-08-14 Farmasoytisk aktivt morfolinol

Country Status (30)

Country Link
US (2) US6274579B1 (no)
EP (2) EP1829544A1 (no)
JP (1) JP2002501025A (no)
KR (1) KR100568063B1 (no)
CN (2) CN1255389C (no)
AP (1) AP1229A (no)
AT (1) ATE365042T1 (no)
AU (1) AU755536B2 (no)
BR (1) BR9907203A (no)
CA (1) CA2318268A1 (no)
CY (1) CY1106828T1 (no)
DE (1) DE69936335T2 (no)
DK (1) DK1047428T3 (no)
EA (1) EA002410B1 (no)
EE (1) EE04452B1 (no)
ES (1) ES2288012T3 (no)
HR (2) HRP20000494B1 (no)
HU (1) HUP0100900A3 (no)
ID (1) ID26334A (no)
IL (2) IL137346A0 (no)
IS (1) IS2494B (no)
NO (2) NO326878B1 (no)
NZ (3) NZ520349A (no)
PL (1) PL193622B1 (no)
PT (1) PT1047428E (no)
SG (1) SG115489A1 (no)
SK (1) SK10912000A3 (no)
TR (1) TR200002126T2 (no)
WO (1) WO1999037305A1 (no)
YU (1) YU67102A (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
WO1999038503A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmacological uses of optically pure (+)-bupropion
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
AU7750100A (en) * 1999-10-13 2001-04-23 Glaxo Group Limited Method for the treatment of obesity
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
CA2365428C (en) * 2000-12-21 2008-10-21 Brasscorp Limited Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US7109198B2 (en) 2002-05-17 2006-09-19 Duke University Method for treating obesity
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
ATE413882T1 (de) * 2002-08-23 2008-11-15 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin- wiederaufnahme-inhibitoren
CA2522708C (en) 2003-04-29 2013-05-28 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
WO2005044809A1 (en) * 2003-10-27 2005-05-19 Smithkline Beecham Corporation Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s, 3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
KR20060128995A (ko) * 2004-01-13 2006-12-14 듀크 유니버시티 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2005110405A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
CA2635261A1 (en) * 2006-01-03 2007-07-12 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
TWI504419B (zh) 2006-11-09 2015-10-21 Orexigen Therapeutics Inc 層狀醫藥調配物
JP2010508997A (ja) 2006-11-09 2010-03-25 オレキシジェン・セラピューティクス・インコーポレーテッド 減量薬を投与するための方法
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
EP2419400A1 (en) 2009-04-15 2012-02-22 Research Triangle Institute Monoamine reuptake inhibitors
RU2616496C2 (ru) 2010-01-11 2017-04-17 Ориксиджен Терапьютикс, Инк. Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты)
JP2013526583A (ja) 2010-05-21 2013-06-24 リサーチ・トライアングル・インスティチュート フェニルモルホリンおよびその類似体
JP5952267B2 (ja) 2010-05-21 2016-07-13 リサーチ・トライアングル・インスティチュート 薬物依存を処置するためのヒドロキシブプロピオン類似体（政府支援研究または開発）
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
DK2858640T3 (da) 2012-06-06 2020-06-29 Nalpropion Pharmaceuticals Llc Sammensætning til anvendelse i en fremgangsmåde til behandling af overvægt og fedme hos patienter med høj cardiovaskulær risiko
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
NZ529316A (en) 2004-05-28
KR100568063B1 (ko) 2006-04-07
DE69936335T2 (de) 2008-02-28
EA002410B1 (ru) 2002-04-25
US20020019396A1 (en) 2002-02-14
IS5568A (is) 2000-07-20
KR20010034285A (ko) 2001-04-25
PT1047428E (pt) 2007-09-07
HUP0100900A3 (en) 2002-08-28
EP1047428B1 (en) 2007-06-20
EP1047428A1 (en) 2000-11-02
YU67102A (sh) 2004-12-31
AU2328099A (en) 1999-08-09
BR9907203A (pt) 2000-10-17
CN1255389C (zh) 2006-05-10
EP1047428A4 (en) 2001-12-19
DK1047428T3 (da) 2007-10-08
NO20003721D0 (no) 2000-07-20
TR200002126T2 (tr) 2000-12-21
CY1106828T1 (el) 2012-05-23
EP1829544A1 (en) 2007-09-05
NZ520349A (en) 2004-02-27
ES2288012T3 (es) 2007-12-16
HRP20000494B1 (en) 2009-02-28
AU755536B2 (en) 2002-12-12
HRP20000494A2 (en) 2000-12-31
EE04452B1 (et) 2005-04-15
US6391875B2 (en) 2002-05-21
SK10912000A3 (sk) 2001-04-09
EA200000691A1 (ru) 2001-04-23
DE69936335D1 (de) 2007-08-02
HRP20051024A2 (hr) 2006-04-30
IL161942A0 (en) 2005-11-20
WO1999037305A1 (en) 1999-07-29
AP1229A (en) 2003-12-04
NO20083529L (no) 2000-09-19
NZ505809A (en) 2002-09-27
ID26334A (id) 2000-12-14
NO326878B1 (no) 2009-03-09
EE200000438A (et) 2001-12-17
CA2318268A1 (en) 1999-07-29
IS2494B (is) 2009-02-15
SG115489A1 (en) 2005-10-28
AP2000001869A0 (en) 2000-09-30
PL193622B1 (pl) 2007-02-28
IL137346A0 (en) 2001-07-24
JP2002501025A (ja) 2002-01-15
HUP0100900A2 (hu) 2002-05-29
US6274579B1 (en) 2001-08-14
ATE365042T1 (de) 2007-07-15
CN1528753A (zh) 2004-09-15
CN1294513A (zh) 2001-05-09
CN1203858C (zh) 2005-06-01
PL342012A1 (en) 2001-05-07

Similar Documents

Publication Publication Date Title
NO20003721L (no) Farmasøytisk aktivt morfolinol
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
HUP0104258A2 (hu) HMG-CoA reduktáz inhibítort tartalmazó stabil gyógyszerkészítmények
JP2002501025A5 (no)
MY162068A (en) Formulation of human antibodies for treating tnf-(alpha) associated disorders
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
BR0103169A (pt) Composição farmacêutica para o tratamento do distúrbio de hiperatividade de déficit de atenção (adhd)
BR9917007A (pt) Moduladores de ccr5
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
DK0678023T3 (da) Anvendelse af riluzol ved fremstilling af lægemidler til behandling af Parkinsons sygdom og parkinsonisme-syndromer
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
GB2373726B (en) Pharmaceutical formulations containing zolmitriptan
ATE412407T1 (de) Arzneimittel zubereitung enthaltend 2-amino-2-ä2- (4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
ATE273693T1 (de) Proteinhaltige arzneimittel
PT1050301E (pt) Composições medicinais contendo 2-amino-2-[2-(4- octilfenil)etil]propano-1,3-diol
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
MY117960A (en) A new salt
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral
SE9800905D0 (sv) New therapy in glomerulonephritis
HUP0204528A2 (en) Use of de deramciclane for preparation of pharmaceutical composition available for treatment of disorders relating to serotonergic system
YU46300A (sh) Farmaceutski aktivni morfolinol
CA2426492A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
HUP0103544A2 (hu) (R)-3-(N,N-diciklobutil amino)-8-fluor-3,4dihidro-2H-1-benzopirán-5karboxamid-hidrogén-(2R,3R)tartarát monohidrátot és paroxelint tartalmazó gyógyszerkészítmény és eljárás az előállítására
SE0102886D0 (sv) New formulation
SE0102888D0 (sv) New formulation

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees